一种新型的大鼠血浆中阿霉素含量测定方法
|
摘要
目的建立大鼠血液中阿霉素(Dox)含量测定的新方法。方法采用荧光分光光度法测定大鼠血浆中的Dox,建立了一种快速、简便、灵敏的定量测定大鼠血浆中Dox及CS-Dox含量的方法。结果在0.1～15.0μg/ml的范围内具有良好的线性关系,回归方程为Y=16.944X+0.6796,R2=0.9997。该方法的日内精密度和日间精密度的RSD均小于2.5%,Dox及CS-Dox的提取回收率均大于84%,表明该检测方法回收率良好。结论所建方法成本低、快速、简便、灵敏,适用于大鼠血浆中Dox的含量测定,同时为Dox及CS-Dox大鼠药代动力学研究提供了可靠的分析方法。
Objective:To establish a new method for determining the content of doxorubicin(Dox) in rat plasma. Methods:Dox in rat plasma was determined by fluorescence spectrophotometry. A rapid, simple and sensitive method for the quantitative determination of chondroitin sulfate-doxorubicin in rat plasma was established. Results:A good positive linear relationship was shown in the mass concentration range of Dox 0.1-15.0 μg/mL. The regression equation was Y=16.944 X+0.6796,R2 = 0.9997. The RSDs of Dox and CS-Dox within-day and between-day were less than 2.5%, and the extraction recovery of Dox and CS-Dox was greater than 84%. The results indicated that this method has high recovery rate. Conclusion:The assay is inexpensive, simple, precise, sensitive and suitable for the determination of doxorubicin in rat plasma. At the same time, it provides a reliable analytical method for the pharmacokinetic study of Dox and CS-Dox in rats.
Objective:To establish a new method for determining the content of doxorubicin(Dox) in rat plasma. Methods:Dox in rat plasma was determined by fluorescence spectrophotometry. A rapid, simple and sensitive method for the quantitative determination of chondroitin sulfate-doxorubicin in rat plasma was established. Results:A good positive linear relationship was shown in the mass concentration range of Dox 0.1-15.0 μg/mL. The regression equation was Y=16.944 X+0.6796,R2 = 0.9997. The RSDs of Dox and CS-Dox within-day and between-day were less than 2.5%, and the extraction recovery of Dox and CS-Dox was greater than 84%. The results indicated that this method has high recovery rate. Conclusion:The assay is inexpensive, simple, precise, sensitive and suitable for the determination of doxorubicin in rat plasma. At the same time, it provides a reliable analytical method for the pharmacokinetic study of Dox and CS-Dox in rats.
引文
[1] Hernán Cortés-Funes,Coronado C.Role of anthracyclines in the era of targeted therapy[J].Cardiovascular Toxicology,2007,7:56-60.
[2] Minotti G,Menna P,Salvatorelli E,Cairo G,Gianni L (2004) Anthracyclines:molecular advancesand pharmacologic developments in antitumor activity and cardiotoxicity[J].Pharmacol Rev,2004,56:185-229.
[3] 王云娟,沈晓梅,赖洵,等.吡喃阿霉素治疗急性白血病[J].中国肿瘤临床与康复,2002,9(6):17-19.
[4] 林志兰.脂质体阿霉素治疗非霍奇金淋巴瘤的临床疗效与安全性研究[J].中国医学创新,2016,13:92-94.
[5] Aydinlik S,Erkisa M,Cevatemre B,et al.Enhanced cytotoxic activity of doxorubicin through the inhibition of autophagy in triple negative breast cancer cell line[J].Biochim Biophys Acta,2017,1861:49-57.
[6] Gervais R,Le Caer,Hervé,Monnet I,et al.Second-Line Oral Chemotherapy (Lomustine,Cyclophosphamide,Etoposide) Versus Intravenous Therapy (Cyclophosphamide,Doxorubicin,and Vincristine) in Patients With Relapsed Small Cell Lung Cancer:A Randomized Phase II Study of GFPC 0501[J].Clinical Lung Cancer,2015,16:100-105.
[7] Pi F,Zhang H,Li H,et al.RNA Nanoparticles Harboring Annexin A2 Aptamer Can Target Ovarian Cancer for Tumor-Specific Doxorubicin Delivery[J].Nanomedicine:nanotechnology,biology,and medicine,2016,13(3):1183-1193.
[8] Feng R,Zhai W L,Yang H Y,et al.Induction of ER stress protects gastric cancer cells against apoptosis induced by cisplatin and doxorubicin through activation of p38 MAPK[J].Biochemical & Biophysical Research Communications,2011,406:299-304.
[9] Fu F,Wen S,Zhu J,et al.Encapsulation of doxorubicin within lactobionic acid-modified multifunctional poly(amidoamine) dendrimers for targeted therapy of liver cancer cells[J].Journal of Controlled Release,2015,213:31-32.
[10] Patil R R,Guhagarkar S A,Devarajan P V.Engineered nanocarriers of doxorubicin:a current update.[J].Critical Reviews in Therapeutic Drug Carrier Systems,2008,25:1-61.
[11] Laura A A,Gilliam,Jennifer S,et al.Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy[J].Muscle & Nerve,2011,43:94-102.
[12] Müller AJ,Letelier M E,Galleguillos M A,et al.Comparison of the antioxidant effects of synovial fluid from equine metacarpophalangeal joints with those of hyaluronic acid and chondroitin sulfate.[J].American Journal of Veterinary Research,2010,71(4):399-404.
[13] Domagala F,Martin G,Bogdanowicz P,et al.Inhibition of interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1:potential mechanism for Diacerein effects in osteoarthritis.[J].Biorheology,2006,43(3-4):577-587.
[14] Kaplan M,Aviram M.Macrophage plasma membrane chondroitin sulfate proteoglycan binds oxidized low-density lipoprotein-Atherosclerosis[J].Atherosclerosis,2000,149:5-17.
[15] 刘克为,迟·依荷巴丽,吕静.鲨鱼软骨素联合化疗治疗晚期非小细胞肺癌疗效观察[J].中国肿瘤临床与康复,2009:167-169.
[16] 孙习鹏,万丽丽,徐志儒,等.高效液相色谱法测定大鼠血浆及组织中多柔比星含量[J].中国药物应用与监测,2010,4:211-215.
[2] Minotti G,Menna P,Salvatorelli E,Cairo G,Gianni L (2004) Anthracyclines:molecular advancesand pharmacologic developments in antitumor activity and cardiotoxicity[J].Pharmacol Rev,2004,56:185-229.
[3] 王云娟,沈晓梅,赖洵,等.吡喃阿霉素治疗急性白血病[J].中国肿瘤临床与康复,2002,9(6):17-19.
[4] 林志兰.脂质体阿霉素治疗非霍奇金淋巴瘤的临床疗效与安全性研究[J].中国医学创新,2016,13:92-94.
[5] Aydinlik S,Erkisa M,Cevatemre B,et al.Enhanced cytotoxic activity of doxorubicin through the inhibition of autophagy in triple negative breast cancer cell line[J].Biochim Biophys Acta,2017,1861:49-57.
[6] Gervais R,Le Caer,Hervé,Monnet I,et al.Second-Line Oral Chemotherapy (Lomustine,Cyclophosphamide,Etoposide) Versus Intravenous Therapy (Cyclophosphamide,Doxorubicin,and Vincristine) in Patients With Relapsed Small Cell Lung Cancer:A Randomized Phase II Study of GFPC 0501[J].Clinical Lung Cancer,2015,16:100-105.
[7] Pi F,Zhang H,Li H,et al.RNA Nanoparticles Harboring Annexin A2 Aptamer Can Target Ovarian Cancer for Tumor-Specific Doxorubicin Delivery[J].Nanomedicine:nanotechnology,biology,and medicine,2016,13(3):1183-1193.
[8] Feng R,Zhai W L,Yang H Y,et al.Induction of ER stress protects gastric cancer cells against apoptosis induced by cisplatin and doxorubicin through activation of p38 MAPK[J].Biochemical & Biophysical Research Communications,2011,406:299-304.
[9] Fu F,Wen S,Zhu J,et al.Encapsulation of doxorubicin within lactobionic acid-modified multifunctional poly(amidoamine) dendrimers for targeted therapy of liver cancer cells[J].Journal of Controlled Release,2015,213:31-32.
[10] Patil R R,Guhagarkar S A,Devarajan P V.Engineered nanocarriers of doxorubicin:a current update.[J].Critical Reviews in Therapeutic Drug Carrier Systems,2008,25:1-61.
[11] Laura A A,Gilliam,Jennifer S,et al.Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy[J].Muscle & Nerve,2011,43:94-102.
[12] Müller AJ,Letelier M E,Galleguillos M A,et al.Comparison of the antioxidant effects of synovial fluid from equine metacarpophalangeal joints with those of hyaluronic acid and chondroitin sulfate.[J].American Journal of Veterinary Research,2010,71(4):399-404.
[13] Domagala F,Martin G,Bogdanowicz P,et al.Inhibition of interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1:potential mechanism for Diacerein effects in osteoarthritis.[J].Biorheology,2006,43(3-4):577-587.
[14] Kaplan M,Aviram M.Macrophage plasma membrane chondroitin sulfate proteoglycan binds oxidized low-density lipoprotein-Atherosclerosis[J].Atherosclerosis,2000,149:5-17.
[15] 刘克为,迟·依荷巴丽,吕静.鲨鱼软骨素联合化疗治疗晚期非小细胞肺癌疗效观察[J].中国肿瘤临床与康复,2009:167-169.
[16] 孙习鹏,万丽丽,徐志儒,等.高效液相色谱法测定大鼠血浆及组织中多柔比星含量[J].中国药物应用与监测,2010,4:211-215.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |